Elite in Leukemia

Dr. Joshua F. Zeidner

University Of North Carolina At Chapel Hill
Chapel Hill, NC
Elite
in Leukemia
Specialties:Hematology Oncology | Hematology | Oncology
Accepting New Patients
OverviewInsuranceLocationsClinical Research

Overview

Joshua Zeidner is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Zeidner and is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Zeidner is currently accepting new patients.

His clinical research consists of co-authoring 65 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 58 articles and participated in 7 clinical trials in the study of Leukemia.

Specialties
Hematology Oncology
Hematology
Oncology
Hospital Affiliations
Unc Hospitals
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  UnitedHealthcare
  •  Humana

Locations

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
101 Manning Dr, Chapel Hill, NC 27514
984-974-1000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 17, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Azacitidine
Study Phase: Phase 1
NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)
NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2025
Intervention Type: Drug
Study Drugs: Carboplatin, Topotecan, Topotecan Hydrochloride, Veliparib
Study Phase: Phase 2
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Biological
Study Drugs: Entinostat, Pembrolizumab
Study Phase: Phase 1
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
A Randomized, Open-label, Controlled, Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults With Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2024
Intervention Type: Drug
Study Drugs: Pevonedistat, Venetoclax, Azacitidine
Study Phase: Phase 2
A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairment or Mild or Moderate Hepatic Impairment
A Phase 1/1b Study of Pevonedistat in Combination With Select Standard of Care Agents in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myelogenous Leukemia, or Advanced Solid Tumors With Severe Renal Impairment or Mild or Moderate Hepatic Impairment
Enrollment Status: Completed
Publish Date: September 05, 2024
Intervention Type: Drug
Study Drugs: Azacitidine, Pevonedistat, Docetaxel, Paclitaxel, Carboplatin
Study Phase: Phase 1
A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 1
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Enrollment Status: Terminated
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
A Phase 1b/2, Open-label Clinical Study to Determine Preliminary Safety and Efficacy of Alvocidib When Administered in Sequence After Decitabine or Azacitidine in Patients With MDS
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Combination product
Study Drugs: Alvocidib, Decitabine, Azacitidine
Study Phase: Phase 1/Phase 2
A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS
A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug, Other
Study Phase: Phase 1
View 9 Less Clinical Trials

65 Total Publications

Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.
Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.
Journal: European journal of haematology
Published: October 02, 2024
Similar Doctors
Expertise in
25
conditions
Dr. Harry P. Erba
Oncology | Hematology | Hematology Oncology
Expertise in
25
conditions
Dr. Harry P. Erba
Oncology | Hematology | Hematology Oncology

Duke Health Integrated Practice Inc

234 Crooked Creek Pkwy, 
Durham, NC 
 (6.8 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Harry Erba is an Oncologist and a Hematologist in Durham, North Carolina. Dr. Erba and is rated as an Elite provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Erba is currently accepting new patients.

Expertise in
18
conditions
Dr. Deborah M. Stephens
Hematology | Oncology | Hematology Oncology
Expertise in
18
conditions
Dr. Deborah M. Stephens
Hematology | Oncology | Hematology Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Deborah Stephens is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Stephens and is rated as an Elite provider by MediFind in the treatment of Leukemia. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Stephens is currently accepting new patients.

Expertise in
15
conditions
Dr. Thomas W. Leblanc
Oncology | Hematology Oncology
Expertise in
15
conditions
Dr. Thomas W. Leblanc
Oncology | Hematology Oncology

Duke Health Integrated Practice Inc

2351 Erwin Rd, 
Durham, NC 
 (9.6 mi)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Leblanc is an Oncologist and a Hematologist Oncology provider in Durham, North Carolina. Dr. Leblanc and is rated as a Distinguished provider by MediFind in the treatment of Leukemia. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Leblanc is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile